Sodium-glucose co-transporter 2 inhibitors (SGLT2i) for hospitalised patients with COVID-19: prospective meta-analysis of randomised trials
Journal article
LANDRAY M. et al, (2024), The Lancet Diabetes and Endocrinology
A blunted nocturnal blood pressure decline is associated with all-cause and cardiovascular mortality.
Journal article
de la Sierra A. et al, (2024), J Hypertens, 42, 1197 - 1202
Efficacy and safety of SGLT2 inhibitors with and without glucagon-like peptide 1 receptor agonists: a SMART-C collaborative meta-analysis of randomised controlled trials.
Journal article
Apperloo EM. et al, (2024), The lancet. Diabetes & endocrinology
Frailty, multimorbidity and polypharmacy: exploratory analyses of the effects of empagliflozin from the EMPA-KIDNEY trial.
Journal article
Mayne KJ. et al, (2024), Clin J Am Soc Nephrol
Artificial Intelligence-Derived Risk Prediction: A Novel Risk Calculator Using Office and Ambulatory Blood Pressure.
Journal article
Guimarães P. et al, (2024), Hypertension
Effects of SGLT2 inhibitors on cause-specific cardiovascular death in patients with chronic kidney disease: a meta-analysis of CKD progression trials.
Journal article
Fletcher RA. et al, (2024), Clin J Am Soc Nephrol
Sodium Glucose Co-transporter 2 Inhibitors and Major Adverse Cardiovascular Outcomes: A SMART-C Collaborative Meta-Analysis.
Journal article
Patel SM. et al, (2024), Circulation
Ambulatory blood pressure monitoring and mortality - Authors' reply.
Journal article
de la Sierra A. et al, (2024), Lancet, 403
Immunomodulatory therapy in children with paediatric inflammatory multisystem syndrome temporally associated with SARS-CoV-2 (PIMS-TS, MIS-C; RECOVERY): a randomised, controlled, open-label, platform trial.
Journal article
RECOVERY Collaborative Group None., (2024), Lancet Child Adolesc Health, 8, 190 - 200
Mechanisms of rosuvastatin-related acute kidney injury following cardiac surgery: the STICS trial.
Journal article
Wijesurendra RS. et al, (2024), Eur Heart J, 45, 629 - 631
Dimethyl fumarate in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial.
Journal article
RECOVERY Collaborative Group None. et al, (2024), Nat Commun, 15
Effects of empagliflozin on progression of chronic kidney disease: a prespecified secondary analysis from the empa-kidney trial.
Journal article
EMPA-KIDNEY Collaborative Group None., (2024), Lancet Diabetes Endocrinol, 12, 39 - 50
Impact of primary kidney disease on the effects of empagliflozin in patients with chronic kidney disease: secondary analyses of the EMPA-KIDNEY trial.
Journal article
EMPA-KIDNEY Collaborative Group None., (2024), The lancet. Diabetes & endocrinology, 12, 51 - 60
Empagliflozin in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial.
Journal article
RECOVERY Collaborative Group None., (2023), Lancet Diabetes Endocrinol, 11, 905 - 914
Evaluation of pragmatic oxygenation measurement as a proxy for Covid-19 severity
Journal article
Swets MC. et al, (2023), Nature Communications, 14
Effects of Empagliflozin on Fluid Overload, Weight and Blood Pressure in Chronic Kidney Disease
Journal article
Mayne K. et al, (2023), Journal of the American Society of Nephrology
UK Kidney Association Clinical Practice Guideline: Sodium-Glucose Co-transporter-2 (SGLT-2) Inhibition in Adults with Kidney Disease 2023 UPDATE.
Journal article
Roddick AJ. et al, (2023), BMC Nephrol, 24
Relationship between clinic and ambulatory blood pressure and mortality: an observational cohort study in 59 124 patients.
Journal article
Staplin N. et al, (2023), Lancet, 401, 2041 - 2050